… Cell Therapy Research Network (CCTRN). Detailed analysis of bone marrow from patients
with ischemic heart disease and left … and clinical studies of stem cell therapy for heart disease. …

… Our results showed that cell therapy is safe and leads to a preserved LVEF. Future trials
should focus on cell types other than BM-MNC, large infarction, and strategies to obtain …

… , cell-based therapies have rapidly emerged as a potential novel therapeutic approach in …
heart disease. After the initial characterization of putative endothelial progenitor cells and their …

… This study shows evidence that autologous cell therapy may be beneficial for patients … the
disease. The rationale behind using stem and progenitor cells as treatment for heart disease is …

… the engraftment of transplanted cells and therapeutic efficiency for ischemic heart diseases.
… cardiac progenitor cells (CPCs) together with MC-HIF1 into the ischemic heart can improve …

… Key inclusion criteria were age (18 years of age and older and younger than 75 years of
age), ischemic heart disease, and management according to guidelines. Patients with an …

… of cells in the context of heart repair, and the most relevant results and current limitations from
clinical trials using cell-based therapies … strategies for stem cell therapy enhancement, with …

… is an experimental therapy that is not … of cell therapies for ischaemic heart disease and
heart failure. Evidence from early trials and systematic reviews has suggested that cell therapy …

… However, further clinical evidence is needed, in order to optimize the timing of cardiac stem
cell therapy in ischemic heart disease and recently also therapy protocols performing cell …

… infarction versus chronic heart failure), the timing of cell therapy and the … heart disease
and related vascular impairments, whose mononuclear cells and endothelial progenitor cells …